Title
PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab
Date Issued
01 March 2016
Access level
metadata only access
Resource Type
review
Author(s)
Dahagam C.
Goud A.
Abdelqader A.
Hendrani A.
Feinstein M.J.
Qamar A.
Joshi P.H.
Swiger K.J.
Byrne K.
Jones S.R.
Blumenthal R.S.
Martin S.S.
Centro Johns Hopkins Ciccarone para la Prevención de las Enfermedades Cardiovasculares
Publisher(s)
Future Medicine Ltd.
Abstract
In this review, we examine alirocumab (Praluent®), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.
Start page
149
End page
157
Volume
12
Issue
2
Language
English
OCDE Knowledge area
Sistema cardiaco, Sistema cardiovascular
Subjects
Scopus EID
2-s2.0-84959923543
PubMed ID
Source
Future Cardiology
ISSN of the container
14796678
Sources of information:
Directorio de Producción Científica
Scopus